One year on, Capricor's stem cell therapy appears to help DMD patients in small study, but investors balk at the data

Repeated setbacks aside, little Capricor has suggested it has generated some long-term data to support its pursuit to garner approval for its stem cell therapy for Duchenne muscular dystrophy, although some of the data appeared to underwhelmed investors.